secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044829
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M
--------------------------------------------------------------------

- Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.
- Adjusted EBITDA improved to $0.8M from $0.3M in prior-year quarter.
- Appointed Keith Myers (former LHC Group CEO) to the board; invested $5.0M in ChemoMouthpiece for 6.64% stake and exclusive U.S. distribution.
- Products now sold in over 1,200 facilities; contracted in 4,000+ hospitals; distributor network expanded to 300+.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/0001493152-24-044829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer